High Sustained Virologic Response Rates of Glecaprevir/Pibrentasvir in Patients With Dosing Interruption or Suboptimal Adherence

INTRODUCTION: Pangenotypic, all-oral direct-acting antivirals, such as glecaprevir/pibrentasvir (G/P), are recommended for treatment of hepatitis C virus (HCV) infection. Concerns exist about the impact on efficacy in patients with suboptimal adherence, particularly with shorter treatment durations....

Descripción completa

Detalles Bibliográficos
Autores principales: Zamor, Philippe J., Brown, Ashley, Dylla, Douglas E., Dillon, John F., Luetkemeyer, Anne F., Feld, Jordan J., Mutimer, David, Ghalib, Reem, Crown, Eric, Lovell, Sandra S., Hu, Yiran, Moreno, Christophe, Nelson, David R., Colombo, Massimo, Papatheodoridis, Georgios, Rockstroh, Juergen K., Skoien, Richard, Lawitz, Eric, Jacobson, Ira M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389353/
https://www.ncbi.nlm.nih.gov/pubmed/34465693
http://dx.doi.org/10.14309/ajg.0000000000001332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389353/
https://www.ncbi.nlm.nih.gov/pubmed/34465693
http://dx.doi.org/10.14309/ajg.0000000000001332

Ejemplares similares